Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Phase 2 Trial
Recent news which mentions Phase 2 Trial
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why Are Vertex Pharmaceuticals Shares Trading Higher Today?
December 01, 2021
Tickers
VRTX
Tags
Biotech
General
Chronic Kidney Disease
From
Benzinga
Mereo BioPharma's Etigilimab/Opdivo Combo Achieves One Complete Response In Cervical Cancer
November 30, 2021
Tickers
BMY
MREO
Tags
MREO
Phase 2 Trial
Penny Stocks
From
Benzinga
Cybin To Test Psychedelic-Assisted Psychotherapy For COVID-Related Distress
November 30, 2021
Tickers
CYBN
Tags
Penny Stocks
Biotech
News
From
Benzinga
After Denying Data Leak, Olema Shares First Data For Lead Program In Breast Cancer Patients
November 30, 2021
Tickers
OLMA
Tags
Small Cap
breast cancer
Benzinga
From
Benzinga
MEI Pharma, Kyowa Kirin Reveal Data From Zandelisib Trial In Follicular Lymphoma
November 30, 2021
Tickers
MEIP
Tags
General
News
Market News
From
Benzinga
First Wave BioPharma Stock Jumps On Niclosamide's Favorable Safety Profile In COVID-19 Related GI Infections
November 30, 2021
Tickers
FWBI
Tags
Trading Ideas
Health Care
Briefs
From
Benzinga
Adagene Shares Jump After FDA Signs Off ADG116/Keytruda Combo Therapy Trial In Solid Tumors
November 30, 2021
Tickers
ADAG
MRK
Tags
MRK
Benzinga
Small Cap
From
Benzinga
Sigilon Therapeutics Issues An Update On Its Early-Stage Hemophilia Study
November 29, 2021
Tickers
SGTX
Tags
Benzinga
General
Hemophilia A
From
Benzinga
NRx Pharma Skyrockets After BriLife COVID-19 Vaccine Data Against Delta Variant
November 26, 2021
Tickers
NRXP
Tags
General
Long Ideas
COVID/19 Coronavirus
From
Benzinga
Selecta's Gene Therapy Trial For Genetic Metabolic Disorder Put On FDA Hold
November 26, 2021
Tickers
SELB
Tags
News
why it's moving
Phase 1 Trial
From
Benzinga
Pfizer Posts Vupanorsen Data From Mid-Stage Cardiovascular Disease Trial
November 24, 2021
Tickers
IONS
PFE
Tags
Briefs
Health Care
Trading Ideas
From
Benzinga
Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial
November 24, 2021
Tickers
GILD
MRK
Tags
GILD
Phase 2 Trial
Briefs
From
Benzinga
FDA Clears Tonix Pharma's Human Trial With Intranasal Oxytocin For Migraine
November 23, 2021
Tickers
TNXP
Tags
Health Care
Trading Ideas
Briefs
From
Benzinga
Imara Changes Primary Endpoint In Mid-Stage Sickle Cell Disease Trial
November 22, 2021
Tickers
IMRA
Tags
IMRA
Benzinga
Phase 2 Trial
From
Benzinga
Affimed's Lymphoma Candidate Shows 100% Objective Response Rate At Highest Dose
November 22, 2021
Tickers
AFMD
Tags
Phase 2 Trial
Movers
Briefs
From
Benzinga
Puma Biotech's Neratinib Fails To Extend Overall Survival In Brain Cancer Trial
November 22, 2021
Tickers
PBYI
Tags
Penny Stocks
Phase 2 Trial
brain cancer
From
Benzinga
Jaguar Health's Posts Crofelemer Data For Chemo-Induced Diarrhea In Breast Cancer Patients
November 19, 2021
Tickers
JAGX
Tags
Movers
Phase 2 Trial
Health Care
From
Benzinga
Roche's Gavreto Conditionally Approved In Europe For RET Fusion-Positive Lung Cancer
November 19, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
RHHBF
General
Phase 1 Trial
From
Benzinga
Merck Pauses Development Of MK-8507 In HIV Infection
November 19, 2021
Tickers
MRK
Tags
Phase 2 Trial
Health Care
HIV
From
Benzinga
Ascendis' Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks
November 19, 2021
Tickers
ASND
Tags
Briefs
FDA
Health Care
From
Benzinga
Connect Biopharma's Mid-Stage Atopic Dermatitis Trial Meets Primary Endpoint
November 19, 2021
Tickers
CNTB
Tags
CNTB
General
News
From
Benzinga
Spark Therapeutics' Hemophilia Gene Therapy Shows Reduction In Bleeding Episodes
November 18, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Benzinga
RHHVF
Health Care
From
Benzinga
Eloxx Shares Slump As Phase 2 Cystic Fibrosis Trial Data Fails To Cheer Investors
November 17, 2021
Tickers
ELOX
VRTX
Tags
VRTX
Market News
News
From
Benzinga
Imara's Thalassemia Candidate Shows Reduced Transfusion Burden At Higher Dose
November 16, 2021
Tickers
IMRA
Tags
Briefs
Trading Ideas
Health Care
From
Benzinga
InflaRx's Vilobelimab Shows Encouraging Action Against Rare Autoimmune Disorder
November 15, 2021
Tickers
IFRX
Tags
Movers
Phase 2 Trial
Health Care
From
Benzinga
Novocure Posts Data For Tumor Treating Fields In Brain Tumor Trial
November 15, 2021
Tickers
NVCR
Tags
Phase 2 Trial
Health Care
Biotech
From
Benzinga
AstraZeneca, Moderna Shares Early Cut Data For mRNA Candidate In Heart Failure
November 15, 2021
Tickers
AZN
MRNA
Tags
General
Benzinga
AZN
From
Benzinga
Bristol Myers Squibb, Janssen Move Closer To Phase 3 For Blood Thinner Candidate
November 15, 2021
Tickers
BMY
JNJ
Tags
Benzinga
JNJ
Trading Ideas
From
Benzinga
Iovance's Lifileucel Combo Shows Encouraging Response Rates In Advanced Cancers
November 15, 2021
Tickers
IOVA
MRK
Tags
MRK
Benzinga
Movers
From
Benzinga
Adaptimmune Bullish On Meeting Endpoint For Soft Tissue Cancer Trial
November 11, 2021
Tickers
ADAP
Tags
Trading Ideas
Health Care
Briefs
From
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.